
Join us as we speak with Ideaya Biosciences to learn about their latest exciting molecules under development. We'll be covering: promising progress in uveal melanoma with darovasertib (PKCi) + crizotinib; new results in MTAP deficient settings with MAT2Ai + PRMT5i; and next generation molecules for PARPi resistant tumours.